If you have been considering a GLP-1 medication, you have probably seen the clinical trial numbers: semaglutide produces approximately 15–17% weight loss. Tirzepatide delivers around 20%. For a 250-pound person, that is 37–50 pounds gone.
Then there is the real world.
In June 2025, researchers from NYU Langone Health and NYC Health + Hospitals presented a study at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Scientific Meeting that compared GLP-1 medication outcomes to bariatric surgery using electronic health records from 51,085 patients. The results were sobering.
| Treatment | Average Weight Loss (2 years) | % Body Weight Lost |
|---|---|---|
| Bariatric surgery (sleeve/bypass) | 58 lbs | 24% |
| GLP-1 medications (6+ months on Rx) | 12 lbs | 4.7% |
| GLP-1 medications (full year continuous) | — | 7% |
Surgery patients lost five times more weight. Even patients who stayed on GLP-1 therapy continuously for a full year — the most adherent group — achieved only 7% weight loss, less than half what clinical trials predict.
This is not a failure of the medications. The science is real. The clinical trial data is accurate. What this study reveals is a failure of the system in which these medications are used. And understanding the gap is essential for anyone who wants to be on the right side of it.
Why Clinical Trials Show Better Results
Clinical trials are designed to measure what a medication can do under ideal conditions. Participants are screened, monitored, counseled, and supported throughout the trial. They receive the medication for free, titrate on schedule, attend regular follow-up visits, and receive dietary and exercise guidance.
Real-world patients face a completely different reality.
1. Dropout and Discontinuation
This is the single largest driver of the gap. The NYU study found that as many as 70% of patients may discontinue GLP-1 treatment within one year. The reasons are predictable: cost ($300–$1,300/month without insurance), side effects (nausea is the most common reason cited), insurance denial or loss of coverage, and supply disruptions.
In clinical trials, participants are committed for the duration and receive the medication at no cost. In the real world, financial barriers alone filter out a large portion of patients before they reach therapeutic doses.
2. Incomplete Titration
GLP-1 medications require gradual dose increases (titration) over weeks or months to reach the therapeutic dose. Semaglutide starts at 0.25 mg and titrates up to 2.4 mg over approximately 16–20 weeks. Many real-world patients never complete this titration — they stop at a sub-therapeutic dose due to side effects, cost increases at higher doses, or lack of follow-up.
A patient on semaglutide 0.5 mg is not on the same medication, in effect, as a patient on 2.4 mg. The clinical trial results reflect the full therapeutic dose. Real-world averages include everyone who stalled at lower doses.
3. Inadequate Follow-Up
Clinical trial participants receive regular monitoring, dietary counseling, and medical check-ins. Many real-world GLP-1 prescriptions come through telehealth platforms with minimal follow-up after the initial consultation. Without ongoing clinical support, patients are less likely to manage side effects effectively, adjust dosing appropriately, or maintain the dietary and exercise modifications that complement the medication.
4. Patient Selection
Clinical trials enroll patients who meet strict criteria and agree to follow the study protocol. Real-world prescribing is broader — it includes patients with multiple comorbidities, complex medication regimens, and varying levels of commitment to lifestyle changes. This is not a criticism of patients; it is a reflection of the difference between a controlled research environment and the messy reality of healthcare delivery.
What Tirzepatide Looks Like in the Real World
The NYU study noted that among GLP-1 medications, tirzepatide (Mounjaro/Zepbound) was associated with the best real-world results, averaging 8.9% weight loss after two years. This is consistent with tirzepatide's superior efficacy in clinical trials (SURMOUNT-5 showed 20.2% vs semaglutide's 13.7%), but the real-world number is still less than half the clinical trial result.
The pattern holds: whichever medication performs better in trials also performs better in practice, but the absolute numbers are significantly lower across the board.
What This Means — and What It Does Not Mean
This study does NOT mean GLP-1 medications do not work. It means that the conditions required for GLP-1 medications to produce clinical-trial-level results — consistent dosing, completed titration, ongoing adherence, lifestyle support — are not being met for most patients in the current healthcare system.
The medication works. The system around it frequently does not. And that distinction matters enormously for anyone deciding whether to start GLP-1 therapy.
How to Be in the 7%, Not the 4.7%
The patients who do achieve meaningful weight loss on GLP-1 medications share common characteristics. None of them are surprising, but all of them require deliberate effort:
Complete the titration. Get to the therapeutic dose. Work with your prescriber to manage side effects during the ramp-up rather than stopping early. The medication's efficacy increases significantly at higher doses.
Stay on treatment. Continuity matters. The NYU study showed that patients on continuous therapy for a full year achieved 7% weight loss — nearly 50% more than the average. Every month you remain on therapy compounds the benefit.
Address the cost barrier proactively. Explore manufacturer savings programs, the Medicare GLP-1 Bridge (launching July 2026), employer insurance coverage, and HSA/FSA eligibility. Financial disruption is the most preventable cause of discontinuation.
Find a provider with real follow-up. Not all telehealth platforms are equal. Providers that include regular check-ins, dose adjustment consultations, and dietitian support produce better outcomes than platforms that treat the prescription as a one-time transaction.
Protein and resistance training are not optional. GLP-1 medications reduce appetite, which means caloric intake drops. If protein intake and resistance training are not maintained, muscle loss accelerates and metabolic adaptation works against you. Aim for 0.8–1.0 grams of protein per pound of lean body mass and resistance train at least 2–3 times per week.
When Surgery Makes More Sense
The NYU data does not mean everyone should get surgery instead of GLP-1 medication. Surgery carries its own risks, recovery requirements, and long-term complications. But for patients with severe obesity (BMI 40+) or significant comorbidities who have not achieved adequate results with medication, the data supports having an honest conversation about bariatric surgery as an option — not as a last resort, but as a potentially more effective first-line treatment for certain patients.
The lead study author, Dr. Avery Brown of NYU Langone, put it directly: patients who get insufficient weight loss with GLP-1s or have challenges with compliance should consider bariatric surgery as an option, potentially even in combination with medication.
The Bottom Line
The 15–21% weight loss numbers from clinical trials are real. But they represent what is possible under ideal conditions — conditions that most patients in the current system do not experience. The real-world average is much lower, driven primarily by early discontinuation, incomplete dosing, and inadequate support.
The gap is not inevitable. It is the distance between how the medication is designed to be used and how it is actually being used. Closing that gap is a matter of provider quality, patient support, financial access, and individual commitment.
Find a Provider That Supports Your Success
Compare telehealth providers by follow-up support, pricing transparency, and titration guidance — not just the prescription.
Compare Providers